Share this content on Facebook!
01 Jan 2015

The authors compared the current recommended therapy for uncomplicated malaria in children in Papua New Guinea, artemether-lumefantrine, with a different combination therapy, artemisinin-naphthoquine. Using a randomized, controlled trial study design including 186 children with Plasmodium falciparum infections and 47 children with Plasmodium vivax infections, the researchers found that artemisinin-naphthoquine was non-inferior to (no worse than) artemether-lumefantrine for treating Plasmodium falciparum (a difference of 2.2% [95% confidence interval ?3.0% to 8.4%] for reappearance of infection within 42 days) but was more effective for treating Plasmodium vivax (a difference 70.0% [95% confidence interval 40.9%-87.2%] for reappearance of infection within 42 days). The authors conclude, "[t]he efficacy, tolerability, and safety of three daily doses of artemisinin-naphthoquine suggest that this regimen should be considered together with other currently available effective [artemisinin combination therapies] for treatment of uncomplicated malaria in [Papua New Guinea] and similar epidemiologic settings with transmission of multiple Plasmodium species." Story Source: The above story is based on materials provided by PLOS . Note: Materials may be edited for content and length. Journal Reference: Moses Laman, Brioni R. Moore, John M. Benjamin, Gumul Yadi, Cathy Bona, Jonathan Warrel, Johanna H. Kattenberg, Tamarah Koleala, Laurens Manning, Bernadine Kasian, Leanne J. Robinson, Naomi Sambale, Lina Lorry, Stephan Karl, Wendy A. Davis, Anna Rosanas-Urgell, Ivo Mueller, Peter M.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2014/12/141230145200.htm


To read more about malarone malaria tablets please visit http://www.malariaprevention.co.uk/malarone-atovaquone-proguanil/


Comments

There isn't any comment in this page yet!

Do you want to be the first commenter?


New Comment

Full Name:
E-Mail Address:
Your website (if exists):
Your Comment:
Security code: